Oral Cyclosporine in Chronic Obstructive Pulmonary Disease

NCT ID: NCT00974142

Last Updated: 2025-06-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 43 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-09-30
• Study Completion Date: 2016-12-31

Brief Summary

This is a randomized, double-blinded, placebo-controlled trial of oral Cyclosporine A (CsA) in patients with advanced stage chronic obstructive pulmonary disease. The purpose of the study is to evaluate the safety and effectiveness of CsA as a therapy for the adaptive immune response in advanced stage Chronic Obstructive Pulmonary Disease (COPD).

Subjects between 45 and 80 years of age with a confirmed diagnosis of advanced stage COPD, not responsive to conventional inhaler therapy, who meet all the study requirements, will be enrolled in this study. A total of 30 subjects of either sex will be enrolled in this study.

Conditions

Chronic Obstructive Pulmonary Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Cyclosporine

Group Type: EXPERIMENTAL

Cyclosporine

Intervention Type: DRUG

Fifteen patients will receive cyclosporine at an initial dosing of 3.0 mg/kg/day.

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Fifteen patients will receive will receive placebo.

Interventions

Cyclosporine

Fifteen patients will receive cyclosporine at an initial dosing of 3.0 mg/kg/day.

Intervention Type: DRUG

Placebo

Fifteen patients will receive will receive placebo.

Intervention Type: DRUG

Other Intervention Names

Neoral

Eligibility Criteria

Inclusion Criteria

• Age between 45 and 80 years
• A confirmed diagnosis of advanced stage COPD, using current accepted diagnostic criteria, including clinical/laboratory findings, pulmonary function tests, and appropriate history to exclude other disorders that could explain their lung disease. The accepted range of forced expiratory volume at one second will include 25% ≤ forced expiratory volume at one second ≤ 60%
• Subjects agree to maintain a stable medication regimen in the absence of a disease flare
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
• carbon dioxide partial pressure < 45 mm Hg, room air oxyhemoglobin saturation > 85%
• A willingness to participate in all portions of the protocol, including serial bronchoscopy, requisite surveillances, and ancillary immunologic studies in follow-up visits at this institution
• For woman of childbearing age, a negative pregnancy test, and a willingness to use two methods of contraception, or abstinence
• An ability and willingness to provide written informed consent

Exclusion Criteria

• Three, or more exacerbations of lower respiratory disease in the past year requiring systemic corticosteroids, or one exacerbation requiring hospitalization in the past 6 months
• Intubation for COPD, or other cause of respiratory failure in the past year
• Use of immunosuppressive therapy including oral prednisone > 10mg per day other than aerosolized corticosteroids, anytime within three months prior to participation
• Evidence for an opportunistic infection/colonization of the airways, i.e., non-bacterial
• Evidence for systemic illness including hematologic disorders (defined by an absolute neutrophil count (ANC) < 4000 /mL and platelets < 120,000/mL), cirrhosis, or hepatic insufficiency (total bilirubin, or alkaline phosphatase > 1.5 x normal, serum glutamate oxaloacetate transaminase, or serum glutamate pyruvate transaminase > 1.2 x normal values), or a coagulopathy (INR > 1.4), seizure disorder
• Evidence for renal insufficiency with a calculated creatinine clearance using the Cockcroft and Gault's method of < 80 ml/min for males and < 70 ml/min for females, or serum creatinine > 1.4 mg/dL.
• Evidence of coronary artery disease by history, e.g., angina or history of myocardial infarction within the past 12 months, unless corrected by coronary artery bypass graft within < 5 years, and asymptomatic since
• Evidence for systemic abnormal renal function manifested by uncontrolled hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure >90 mmHg), hyperkalemia (serum potassium > 5.0 meq/dl, and/or elevated serum potassium above the normal range for the subject's age)
• Pregnancy or lactation, or inability to take contraception during and for 6 months following treatment
• Positive HIV, or hepatitis B or C serology, or another active infection
• Current or past history of cancer excluding basal or squamous cell skin cancer
• Undiagnosed pulmonary nodule requiring diagnostic evaluation
• Weight loss > 10% usual body weight over the past 6 months or a BMI < 18
• Known hypersensitivity or allergy to cyclosporine
• Concurrent participation in other clinical trials within the prior month
• Known medical or psychological condition (severe personality disorder or mental illness) that would not permit the subject to complete the trial or sign informed consent
• Autoimmune disorders or other disorders with suspected systemic immune involvement
• Active smoking history or urinary cotinine > 2
• Hypersensitivity to midazolam or narcotics which would not allow bronchoscopy sedation
• Concurrent use of drugs with a known interaction with cyclosporine

• Minimum Eligible Age: 45 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role: collaborator

Michael Donahoe

OTHER

Sponsor Role: lead

Responsible Party

Michael Donahoe

Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Michael Donahoe, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh

Locations

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

Countries

United States

Other Identifiers

PRO09050330

Identifier Type: -

Identifier Source: org_study_id